Effect of Dahuang Danpi Decoction on Lactobacillus bulgaricus growth and metabolism

In vitro study

Chaoqun Li, MD\textsuperscript{a}, Jiayu Zhang, MD\textsuperscript{b,g}, Hua Xu, MD\textsuperscript{a,*}, Yabin Chen, MD\textsuperscript{a}, Shuoshuo Gao, MD\textsuperscript{a}, Shu-ning Guo, MM\textsuperscript{a}, Bang Huang, MM\textsuperscript{a}, Ruiy Gao, MM\textsuperscript{a}, Zhicheng Long, MM\textsuperscript{a}, Meirong Jiang, MM\textsuperscript{a}

Abstract
Gut flora plays an essential role in disease and health. A traditional Chinese herb formula, Dahuang Danpi Decoction (DDD) can alleviate several gastrointestinal diseases.

In the present study, we assessed the effect of DDD on the growth and metabolism of Lactobacillus bulgaricus. L. bulgaricus was cultured in MRS with 40 mg/ml (high), 10 mg/ml (medium), and 2.5 mg/ml (low) of DDD, Ceftriaxone and blank (control). The growth of L. bulgaricus was measured by optical density. The levels of L-lactic acid and D-lactic acid were also measured.

Compared to the control group, the concentrations of L. bulgaricus in the medium and high concentrations DDD groups were significantly higher ($P < .001$ for all), while the concentrations of L. bulgaricus in the ceftriaxone groups were significantly lower. In the 3 DDD groups, the L-lactic acid levels were significantly higher than those in the control group and the ceftriaxone groups ($P < .001$ for all), and the L-lactic acid level was the highest in the high DDD group. Similarly, the D-lactic acid level in the high concentration DDD group was significantly higher than those in the medium and low concentration DDD groups, the control group and the ceftriaxone groups. Both the L-lactic acid and D-lactic acid levels were lower than those in the control group and the DDD groups.

DDD could dose-dependently promote the growth of L. bulgaricus and enhance the secretion of L-lactic acid and D-lactic acid, which suggests DDD may be able to interact with the probiotics, improve the gut microbiota, and serve in the prevention and treatment of dysbiosis.

Abbreviation: DDD = Dahuang Danpi Decoction.

Keywords: bulgarian lactobacillus, Dahuang Danpi Decoction, growth curve, gut microbiota, lactic acid, metabolism

1. Introduction
The bacterial inhabitants of the human gastrointestinal tract constitute an enormously complex ecosystem that includes both aerobic and anaerobic microorganisms.\textsuperscript{[1]} The relevance and effect of resident bacteria on a host’s physiology and pathology has been well documented.\textsuperscript{[2]} Major functions of the gut microflora include metabolic activities that result in salvage of energy and absorbable nutrients, trophic effects on intestinal epithelia and immune structure and function, and protection of the colonized host against invasion by alien microbes.\textsuperscript{[3]} Gut flora may play an essential role in certain pathological disorders, including multisystem organ failure, colon cancer, and even cardiovascular disease.\textsuperscript{[4]} Studies have shown therapeutic manipulation of the enteric microflora would benefit patients with irritable bowel syndrome, inflammatory bowel disease, and Clostridium difficile infection.\textsuperscript{[5–7]}

Several attempts have been made to target the gut microbiota. Studies have shown that traditional Chinese herb could induce structural changes in gut microbiota, enrich the amounts of beneficial bacteria and benefit treatment of diabetes and prostate cancer.\textsuperscript{[8,9]} A standardized Chinese herbal formula containing rhubarb and moutan bark, Dahuang Danpi Decoction (DDD), has been used in traditional Chinese medicine for gastrointestinal disease for nearly 2000 years. WF Li et al revealed that DDD could help to lower the level of CRP and the Randsen scores in acute severe pancreatitis,\textsuperscript{[10,11]} and also help to prevent and treat multiple organ dysfunction.\textsuperscript{[12]} However, the mechanism underlying DDD’s impact on these status has barely been elucidated. A recent study revealed that rhubarb extract changed the microbial ecosystem, downregulated key markers of both inflammatory and oxidative stresses in acute-alcohol challenged mice.\textsuperscript{[13]} This study suggests that the gut microbiota might have a pivotal role in the effect of DDD on gastrointestinal disease.
**Lactobacillus bulgaricus** is one of the dominant probiotic strains in the gastrointestinal tract, which binds closely to the intestinal mucosa to form the biological barrier of the intestine and helps to maintain the gut microflora balance. In this study, we aim to evaluate the effect of DDD on *L. bulgaricus* growth and lactic acid metabolite levels, to check DDD’s impact on the gut microflora, which could be one mechanism for the effect of DDD on gastrointestinal disease.

2. Materials and method

2.1. Materials

MRS medium: 63 g of solid MRS (Thermo Fisher Scientific, Cambridge, MA) was dissolved in 1000 ml of distilled water, and sterilized. *L. bulgaricus* lyophilized powder was purchased from Shandong Branch Ke Yi Biological Engineering Co., Ltd (Qingzhou, Shandong, China), and the total number of viable bacteria is about $1.28 \times 10^{10}$ cfu/g.

2.2. Drugs

DDD preparation: According to Zhang Zhongjing “Golden Chamber”, the formula in our study was composed of five herbs, namely: rhubarb 18 g, moutan bark 9 g, peach seed 12 g, waxgourd seeds 30 g, and Glauber’s salt 9 g. Herbs were all provided and quality controlled by Guangzhou Xingyuanchun pharmacy (Guangzhou, Guangdong, China). Each unit of DDD formula yielded 1000 ml of decoction. The decoction was freeze-dried. Lyophilized samples were stored at $-20$ °C. Ceftriaxone sodium was purchased from Wuhan Berkha Bio-medical Co., Ltd (Wuhan, Hubei, China).

2.3. Culture of *L. bulgaricus* and drug administration

We allocate MRS medium into 7 conical flasks. Each conical flask contained 100 ml of MRS medium and 1 g *L. bulgaricus* freeze-dried powder (about $1.28 \times 10^{10}$ cfu/g). The powder was then mixed to make a suspension of bacteria with concentration of about $10^8$ cfu/ml. The 7 bottles were labeled and treated with the following drugs: 1 with blank; 2 to 4 with high, medium and low doses of DDD respectively; 5 to 7 with high, medium and low doses ceftriaxone sodium respectively. The concentration for high, medium and low dose were 40, 10, and 2.5 mg/ml. The fermentation was carried out for 24 hours at $37^\circ$C with 5% CO₂.

2.4. Strain growth stage determination and lactate metabolites measurement

Aliquots (100 μL) were taken every 2 hours for optical density (OD) measurement. Growth curve of *L. bulgaricus* was determined measuring the increase of OD at 600 nm with a UV-1202 UV–VIS spectrophotometer (Thermo Fisher Scientific, Cambridge, MA). The culture medium supernatant was collected at 0, 2, 6, 10, 14, 18, and 22 hours. L and D lactic acid levels were measured by ELISA commercial kit from BIOVISON (E4356, Milpitas, CA). Each measurement was repeated three times and the average was used for later analyses.

2.5. Analysis

Data were analyzed by SPSS 13.0 software (SPSS v13.0) (ISPP Inc., Chicago, IL). Continuous data were presented as mean±standard deviation. Shapiro–Wilk test was applied to test the normality of data. Repeated measures ANOVA test was used to analyze the levels of OD, L-lactic acid and D-lactic acid levels at different time points in different groups. Mauchly test was used to test the sphericity, and correction of the degree of freedom was applied if necessary. Multiple comparison between the groups was performed using S-L-D method. All tests were two-tailed, and statistical significance was considered to be $P<.05$.

3. Results

3.1. Effects of Dahuang Danpi Decoction and ceftriaxone on *L. bulgaricus* in vitro growth

The OD values of the *L. bulgaricus* in each MRS medium are shown in Table 1. As presented, the concentration of *Lactobacillus* at different time points and in different groups were significantly different ($P<.001$). No significant difference in the concentrations of *Lactobacillus* was observed in the low DDD.

| Table 1 | Growth curve of Lactobacillus in different DDD and Ceftriaxone groups ($\lambda = 600$nm). |
|---|---|---|---|---|---|---|
|   | Control | High-DDD | Med-DDD | Low-DDD | High-Cef | Med-Cef | Low-Cef |
| 0 h | $0.55 \pm 0.04^*$ | $0.49 \pm 0.01^*$ | $0.48 \pm 0.03^*$ | $0.51 \pm 0.01^*$ | $0.49 \pm 0.03^*$ | $0.51 \pm 0.004^*$ | $0.54 \pm 0.01^*$ |
| 2 h | $0.65 \pm 0.01^*$ | $0.42 \pm 0.17^*$ | $0.24 \pm 0.28^*$ | $0.80 \pm 0.03^*$ | $0.64 \pm 0.05^*$ | $0.73 \pm 0.05^*$ | $0.73 \pm 0.03^*$ |
| 4 h | $1.01 \pm 0.03^*$ | $0.91 \pm 0.33^*$ | $2.06 \pm 0.11^*$ | $1.6 \pm 0.1^*$ | $0.58 \pm 0.02^*$ | $0.63 \pm 0.03^*$ | $0.65 \pm 0.01^*$ |
| 6 h | $2.64 \pm 0.25^*$ | $1.34 \pm 0.29^*$ | $3.45 \pm 0.11^*$ | $2.62 \pm 0.05^*$ | $1.59 \pm 0.01^*$ | $1.72 \pm 0.04^*$ | $1.73 \pm 0.02^*$ |
| 8 h | $2.98 \pm 0.21^*$ | $1.98 \pm 0.16^*$ | $3.91 \pm 0.59^*$ | $2.97 \pm 0.33^*$ | $1.47 \pm 0.05^*$ | $0.51 \pm 0.13^*$ | $0.57 \pm 0.15^*$ |
| 10 h | $3.56 \pm 0.23^*$ | $2.64 \pm 0.72^*$ | $4.81 \pm 0.47^*$ | $3.82 \pm 0.3^*$ | $1.67 \pm 0.03^*$ | $0.65 \pm 0.19^*$ | $0.66 \pm 0.1^*$ |
| 12 h | $3.62 \pm 0.02^*$ | $2.51 \pm 0.6^*$ | $4.76 \pm 0.05^*$ | $3.78 \pm 0.07^*$ | $0.54 \pm 0.06^*$ | $0.52 \pm 0.07^*$ | $0.59 \pm 0.07^*$ |
| 14 h | $3.93 \pm 0.04^*$ | $3.32 \pm 0.81^*$ | $5.18 \pm 0.59^*$ | $3.77 \pm 0.9^*$ | $0.58 \pm 0.07^*$ | $0.63 \pm 0.04^*$ | $0.67 \pm 0.05^*$ |
| 16 h | $3.72 \pm 0.13^*$ | $6.47 \pm 0.11^*$ | $5.18 \pm 0.25^*$ | $3.7 \pm 0.22^*$ | $0.66 \pm 0.03^*$ | $0.56 \pm 0.17^*$ | $0.59 \pm 0.06^*$ |
| 18 h | $3.82 \pm 0.05^*$ | $6.67 \pm 0.31^*$ | $5.52 \pm 0.22^*$ | $4.16 \pm 0.31^*$ | $0.75 \pm 0.03^*$ | $0.74 \pm 0.05^*$ | $0.66 \pm 0.02^*$ |
| 20 h | $3.7 \pm 0.1^*$ | $6.7 \pm 0.19^*$ | $4.94 \pm 0.59^*$ | $3.48 \pm 0.43^*$ | $0.63 \pm 0.1^*$ | $0.64 \pm 0.08^*$ | $0.61 \pm 0.03^*$ |
| 22 h | $3.73 \pm 0.21^*$ | $6.93 \pm 0.12^*$ | $5.44 \pm 0.12^*$ | $4.02 \pm 0.17^*$ | $0.71 \pm 0.06^*$ | $0.74 \pm 0.02^*$ | $0.68 \pm 0.05^*$ |
| 24 h | $3.52 \pm 0.1^*$ | $6.15 \pm 0.4^*$ | $4.82 \pm 0.33^*$ | $3.45 \pm 0.25^*$ | $0.73 \pm 0.03^*$ | $0.7 \pm 0.01^*$ | $0.58 \pm 0.03^*$ |

Cef = Ceftriaxone sodium, DDD = Dahuang Danpi Decoction.

The concentration for high, medium and low dose were 40 mg/ml, 10 mg/ml, and 2.5 mg/ml.

Continuous variables were presented as Mean±standard deviation.

$^*$ $P<.001$ for comparisons between each group and control group, and $P<.001$ for comparisons between each group and low DDD group.

$^\dagger$ $P<.001$ for comparisons between each group and high concentration Ceftriaxone group, $P<.001$ for comparisons between each group and medium concentration Ceftriaxone group, and $P<.001$ for comparisons between each group and low concentration Ceftriaxone group.
group and the control group. The Lactobacillus concentration in the high DDD group and the medium DDD group was significantly higher than those in the control group and those in the three ceftriaxone groups \((P < .001\) for all). The concentration in the high DDD group was significantly higher than that in the medium DDD group \((P < .001)\). DDD shortened the lag phase of L. bulgaricus (within 2 hours), prolonged the logarithmic phase (2–14 hours) and kept the stable period of high level reproduction (14–22 hours), especially in the 40 mg/ml DDD group. The Lactobacillus concentration in the ceftriaxone groups was significantly lower than that in the control group \((P < .001)\) in all 3 ceftriaxone groups, no significant difference in Lactobacillus concentration was detected \((P = .84)\).

### 3.2. Effects of Dahuang Danpi Decoction and ceftriaxone on L-lactic acid levels

The L-lactic acid concentrations in different groups are shown in Table 2. As shown, the concentrations of L-lactic acid varied significantly at different time points and in different groups \((P < .001)\). We noted no significant changes in the L-lactic acid concentrations in the three ceftriaxone groups over time, and no significant difference was detected in the high and the medium ceftriaxone group \((P = .15)\). Compared to the control group, the concentrations of L-lactic acid were significantly higher in the three DDD groups, while significantly lower in the three ceftriaxone groups \((P < .001)\) for all. The concentrations of L-lactic acid were highest in the high DDD group, followed by the medium DDD group and the low DDD group \((P < .001)\) for all.

### 3.3. Effects of Dahuang Danpi Decoction and ceftriaxone on D-lactic acid levels

The D-lactic acid concentrations in different groups are shown in Table 3. The concentrations of D-lactic acid at different time points and in different groups were significantly different \((P < .001)\). There was no significant difference of D-lactic acid levels between the control group and the medium DDD group \((P = .214)\) and between the control group and the low DDD group \((P = .13)\). The D-lactic acid levels in the high DDD group were significantly higher than those in the control group, the low and medium DDD group, respectively \((P < .001)\) for all. In the three ceftriaxone groups, the levels of D-lactic acid were significantly lower than those in the control group and all three DDD groups \((P < .001)\). Compared to the low ceftriaxone group, the D-lactic acid levels in the medium and the high ceftriaxone group were significantly lower \((P < .001)\) for both, while no significant differences were detected between the medium and the high ceftriaxone group \((P = .14)\).

### 4. Discussion

In this pilot study, we found that Dahuang Danpi Decoction could dose-dependently promote the growth of L. bulgaricus and enhance the secretion of L-lactic acid and D-lactic acid, which are the metabolites of L. bulgaricus. Ceftriaxone could inhibit the growth and the metabolite secretion of L. bulgaricus.

The human gut is a natural reservoir for numerous species of microorganisms. A mutualistic relationship between beneficial
symbionts and commensals is important for the maintenance of health and wellbeing. Alterations in this balance can lead to dysbiosis and ultimately may result in clinical disease expression. Various disease states and treatments, especially antibiotics have profound influences on the presence and levels of various bacteria normally present in the human microbiome. In coeliac disease patients, level of IgA-coated bacteria is reduced and is associated with intestinal dysbiosis. The proportions of phylum Firmicutes and Clostridia were significantly reduced in the diabetic patients. Probiotics have been increasingly used in both prevention and treatment of a variety of diseases, including but not limited to inflammatory bowel disease, C difficile infection, and antibiotic-associated diarrhea. L bulgaricus and other lactic-acid-producing lactobacilli are the main microbiomes classified as probiotic agents, and lactic acid is one of the underlying mechanisms. By producing a high amount of lactic acid, lactic-acid-producing lactobacilli are able to inhibit the growth of other pathogenic microorganisms. In our work, DDD dose-dependently promoted the growth of L bulgaricus in different periods and significantly enhanced the secretion of both L-lactic acid and D-lactic acid, which suggests DDD could exert a dose-dependent modulation on the gut microbiota. The effect of modulation of gut microbiota can be one of the mechanisms of DDD treatment effect of gastrointestinal disease.

Our findings, as well as prior findings, all suggest a modulation effect of rhubarb on gut microbiota. AM Neyrinck et al revealed that rhubarb extract could change the microbial ecosystem, and downregulated key markers of both inflammatory and oxidative stresses in rats. Peng Ying et al found that in the ileum of rhubarb-exposed rats, more bacterial diversity was observed. DDD formula, a form of polypharmacy, has been used in the treatment of gastrointestinal disease for over 2000 years in China. However, the underlying mechanism has barely been elucidated. Together with previous studies, our work suggested that gut microbiota might be involved. Moreover, we revealed that lactic-acid-producing lactobacilli in particular might be involved.

Our study has several limitations. One important limitation is that our study represents an in vitro study, and our results cannot be directly applied to humans. However, our study could be a useful preliminary study to investigate the effect of DDD on gut microbiota. Second, we only checked the effect of DDD on L bulgaricus, while the effect of DDD on other microorganisms remained unclear and the effect of DDD may be affected by other microorganisms. Third, our work is not able to further identify the possible effective ingredients of DDD, which could lead to a more specific treatment plan. Forth, only 1 culture was done in each group. However, the L bulgaricus culture and measurement in our laboratory were quality controlled. Further studies involving other main microorganisms, in vivo studies and exploration of possible effective gradient such as paeonol are required.

Although generally considered safe, some studies have highlighted that probiotics may be ill advised in specific patient populations. Bacteremia, sepsis and meningitis have been described on rare occasions in children treated with probiotics. Our preliminary work suggested DDD could be a new way for prevention and treatment of dysbiosis, and may be able to further regulate the immune and inflammatory response and other disease which are associated with gut microbiota.

In conclusion, our study suggests that Dahuang Danpi Decoction, the Chinese herbal formula could promote the growth of L bulgaricus and enhance metabolite secretion. This treatment revealed a beneficial effect on the import group of probiotics in the gut, which could be 1 mechanism of DDD treatment effect of gastrointestinal disease. Although further studies are in need to determine the in vivo effect, our work provides preliminary evidence that DDD might be able to interact with probiotics, and improve the gut microbiota, and DDD could be a new therapy for prevention and treatment of dysbiosis.

Author contributions
Conceptualization: Chaoqun Li, Jiayu Zhang, Hua Xu, Shoushuo Gao.
Data curation: Chaoqun Li, Yabin Chen, Shoushuo Gao.
Formal analysis: Hua Xu.
Investigation: Hua Xu, Bang Huang.
Methodology: Chaoqun Li, Hua Xu, Yabin Chen, Shu-ning Guo, Meirong Jiang.
Project administration: Jiayu Zhang.
Resources: Ruyi Gao, Zhicheng Long, Meirong Jiang.
Supervision: Chaoqun Li, Hua Xu.
Writing – original draft: Chaoqun Li, Jiayu Zhang, Shoushuo Gao, Bang Huang.
Writing – review & editing: Hua Xu, Yabin Chen, Ruyi Gao.

References

[1] Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology 1984;86:174–93.
[2] Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361:512–9.
[3] Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012;13:620–70.
[4] Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of endogenous choline promotes cardiovascular disease. Nature 2011;472:57–63.
[5] Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620–33.
[6] Antharam VC, Li EC, Ishmael A, et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol 2013;51:2884–92.
[7] Nobak S, Johansson M, Mole G, et al. Alteration of intestinal microbiota is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231–8.
[8] Zhang X, Zhao Y, Zhang M, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One 2012;7:e42529.
[9] Stolarczyk M, Piwowarski JP, Granica S, et al. Extracts from Epilobium sp. herbs, their components and gut microbiota metabolites of Epilobium ellagittannins, urolithins, inhibit hormone-dependent prostate cancer cells-(LNCaP) proliferation and PSA secretion. Phytother Res 2013;27:1842–8.
[10] Wan M-h, Li J, Gong H-l, et al. Clinical observation on the effect of dexamethasone and Chinese herbal decoction for purgation in severe acute pancreatitis patients. Chin J Integr Med 2011;17:141–5.
[11] Li S, Yang J. Clinical observation on treatment of acute severe pancreatitis with integrative Chinese and Western medicine. J Sichuan Tradit Chin Med 2005;23.
[12] Li W-F, Lin Z-F, Chen D-C, et al. Rhabarb in prevention and treatment of multiple organ dysfunction syndrome in traumatic shock. Acad J Second Mil Med Univ 2004;11:006.
[13] Neyrinck AM, Ertexberria U, Tamminnau B, et al. Rhabarb extract prevents hepatic inflammation induced by acute alcohol intake, an effect related to the modulation of the gut microbiota. Mol Nutr Food Res 2016;60:1–2.
[14] Conway P, Gorbach S, Goldin B. Survival of lactic acid bacteria in the human stomach and adherence to intestinal cells. J Dairy Sci 1987;70:1–2.
[15] Round JL, Mazzamanian S. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009;9:313–23.
[16] De Palma G, Nadal I, Medina M, et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol 2010;10:63.

[17] Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PloS One 2010;5:e9085.

[18] Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480–4.

[19] Tannock G. Molecular analysis of the intestinal microflora in IBD. Mucosal Immunol 2008;1:S15–8.

[20] Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010;7:503–14.

[21] Aiba Y, Suzuki N, Kabir AM, et al. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol 1998;93:2097–101.

[22] Peng Y, Wu C, Yang J, et al. Gut microbial diversity in rat model induced by rhubarb. Exp Anim 2014;63:415–22.

[23] De Groote MA, Frank DN, Dowell E, et al. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005;24:278–80.

[24] Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178–81.

[25] Barton LL, Rider ED, Coen RW. Bacteremic infection with Pediococcus: vancomycin-resistant opportunist. Pediatrics 2001;107:775–6.

[26] Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009;461:1282–6.